vs
Side-by-side financial comparison of BIO-RAD LABORATORIES, INC. (BIO) and RAPID MICRO BIOSYSTEMS, INC. (RPID). Click either name above to swap in a different company.
BIO-RAD LABORATORIES, INC. is the larger business by last-quarter revenue ($693.2M vs $11.3M, roughly 61.4× RAPID MICRO BIOSYSTEMS, INC.). BIO-RAD LABORATORIES, INC. runs the higher net margin — 103.9% vs -110.8%, a 214.6% gap on every dollar of revenue. On growth, RAPID MICRO BIOSYSTEMS, INC. posted the faster year-over-year revenue change (37.3% vs 3.9%). BIO-RAD LABORATORIES, INC. produced more free cash flow last quarter ($119.1M vs $-3.3M). Over the past eight quarters, RAPID MICRO BIOSYSTEMS, INC.'s revenue compounded faster (41.8% CAGR vs 6.5%).
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.
Rapid Micro Biosystems, Inc. develops and manufactures automated microbial detection and quality control solutions for the life sciences industry. Its core products serve biopharmaceutical manufacturers, contract development and manufacturing organizations, operating across key global markets including North America, Europe and Asia-Pacific, helping clients cut testing timelines and improve operational efficiency.
BIO vs RPID — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | ||
|---|---|---|
| Revenue | $693.2M | $11.3M |
| Net Profit | $720.0M | $-12.5M |
| Gross Margin | 49.8% | — |
| Operating Margin | -17.2% | -108.2% |
| Net Margin | 103.9% | -110.8% |
| Revenue YoY | 3.9% | 37.3% |
| Net Profit YoY | 200.6% | -29.3% |
| EPS (diluted) | $26.59 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $693.2M | $11.3M | ||
| Q3 25 | $653.0M | $7.8M | ||
| Q2 25 | $651.6M | $7.3M | ||
| Q1 25 | $585.4M | $7.2M | ||
| Q4 24 | $667.5M | $8.2M | ||
| Q3 24 | $649.7M | $7.6M | ||
| Q2 24 | $638.5M | $6.6M | ||
| Q1 24 | $610.8M | $5.6M |
| Q4 25 | $720.0M | $-12.5M | ||
| Q3 25 | $-341.9M | $-11.5M | ||
| Q2 25 | $317.8M | $-11.9M | ||
| Q1 25 | $64.0M | $-11.3M | ||
| Q4 24 | $-715.8M | $-9.7M | ||
| Q3 24 | $653.2M | $-11.3M | ||
| Q2 24 | $-2.2B | $-12.6M | ||
| Q1 24 | $383.9M | $-13.3M |
| Q4 25 | 49.8% | — | ||
| Q3 25 | 52.6% | — | ||
| Q2 25 | 53.0% | — | ||
| Q1 25 | 52.3% | — | ||
| Q4 24 | 51.2% | — | ||
| Q3 24 | 54.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 53.4% | — |
| Q4 25 | -17.2% | -108.2% | ||
| Q3 25 | 10.0% | -145.1% | ||
| Q2 25 | 11.8% | -167.3% | ||
| Q1 25 | 4.0% | -161.8% | ||
| Q4 24 | 8.7% | -124.5% | ||
| Q3 24 | 9.9% | -158.3% | ||
| Q2 24 | 15.9% | -202.1% | ||
| Q1 24 | 7.3% | -254.4% |
| Q4 25 | 103.9% | -110.8% | ||
| Q3 25 | -52.4% | -146.8% | ||
| Q2 25 | 48.8% | -163.3% | ||
| Q1 25 | 10.9% | -156.3% | ||
| Q4 24 | -107.2% | -117.6% | ||
| Q3 24 | 100.5% | -148.9% | ||
| Q2 24 | -339.2% | -190.1% | ||
| Q1 24 | 62.9% | -237.4% |
| Q4 25 | $26.59 | $-0.26 | ||
| Q3 25 | $-12.70 | $-0.26 | ||
| Q2 25 | $11.67 | $-0.27 | ||
| Q1 25 | $2.29 | $-0.26 | ||
| Q4 24 | $-25.89 | $-0.22 | ||
| Q3 24 | $23.34 | $-0.26 | ||
| Q2 24 | $-76.26 | $-0.29 | ||
| Q1 24 | $13.45 | $-0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5B | $20.0M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $7.5B | $33.2M |
| Total Assets | $10.6B | $74.9M |
| Debt / EquityLower = less leverage | 0.16× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5B | $20.0M | ||
| Q3 25 | $1.4B | $18.9M | ||
| Q2 25 | $1.4B | $18.3M | ||
| Q1 25 | $1.7B | $18.9M | ||
| Q4 24 | $1.7B | $16.9M | ||
| Q3 24 | $1.6B | $22.0M | ||
| Q2 24 | $1.6B | $37.1M | ||
| Q1 24 | $1.6B | $22.4M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $7.5B | $33.2M | ||
| Q3 25 | $6.7B | $44.3M | ||
| Q2 25 | $7.1B | $54.5M | ||
| Q1 25 | $6.7B | $65.5M | ||
| Q4 24 | $6.6B | $75.4M | ||
| Q3 24 | $7.5B | $84.4M | ||
| Q2 24 | $6.8B | $94.6M | ||
| Q1 24 | $9.1B | $105.9M |
| Q4 25 | $10.6B | $74.9M | ||
| Q3 25 | $9.7B | $84.4M | ||
| Q2 25 | $10.2B | $75.6M | ||
| Q1 25 | $9.5B | $85.4M | ||
| Q4 24 | $9.4B | $98.2M | ||
| Q3 24 | $10.6B | $105.8M | ||
| Q2 24 | $9.7B | $117.1M | ||
| Q1 24 | $12.6B | $127.7M |
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $164.9M | $-3.2M |
| Free Cash FlowOCF − Capex | $119.1M | $-3.3M |
| FCF MarginFCF / Revenue | 17.2% | -29.6% |
| Capex IntensityCapex / Revenue | 6.6% | 0.8% |
| Cash ConversionOCF / Net Profit | 0.23× | — |
| TTM Free Cash FlowTrailing 4 quarters | $374.6M | $-31.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $164.9M | $-3.2M | ||
| Q3 25 | $120.9M | $-9.1M | ||
| Q2 25 | $116.5M | $-9.7M | ||
| Q1 25 | $129.9M | $-9.1M | ||
| Q4 24 | $124.2M | $-9.9M | ||
| Q3 24 | $163.6M | $-8.6M | ||
| Q2 24 | $97.6M | $-10.1M | ||
| Q1 24 | $69.8M | $-15.5M |
| Q4 25 | $119.1M | $-3.3M | ||
| Q3 25 | $89.2M | $-9.1M | ||
| Q2 25 | $70.8M | $-10.1M | ||
| Q1 25 | $95.5M | $-9.4M | ||
| Q4 24 | $81.2M | $-10.0M | ||
| Q3 24 | $123.4M | $-8.8M | ||
| Q2 24 | $55.4M | $-10.6M | ||
| Q1 24 | $29.6M | $-16.1M |
| Q4 25 | 17.2% | -29.6% | ||
| Q3 25 | 13.7% | -116.4% | ||
| Q2 25 | 10.9% | -138.6% | ||
| Q1 25 | 16.3% | -130.2% | ||
| Q4 24 | 12.2% | -121.8% | ||
| Q3 24 | 19.0% | -116.0% | ||
| Q2 24 | 8.7% | -159.8% | ||
| Q1 24 | 4.8% | -287.1% |
| Q4 25 | 6.6% | 0.8% | ||
| Q3 25 | 4.9% | 0.9% | ||
| Q2 25 | 7.0% | 5.0% | ||
| Q1 25 | 5.9% | 4.4% | ||
| Q4 24 | 6.4% | 1.2% | ||
| Q3 24 | 6.2% | 2.9% | ||
| Q2 24 | 6.6% | 6.9% | ||
| Q1 24 | 6.6% | 10.4% |
| Q4 25 | 0.23× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.37× | — | ||
| Q1 25 | 2.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.18× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
RPID
| Products | $9.3M | 83% |
| Services | $2.0M | 17% |